title: Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.
abstract: This systematic review examines treatment guidelines, efficacy/effectiveness, and tolerability regarding the use of antipsychotics concurrently with psychostimulants in treating aggression and hyperactivity in children and adolescents. Articles examining the concurrent use of antipsychotics and psychostimulants to treat comorbid attention deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs) were identified and their results were summarized and critically analyzed. Antipsychotic and stimulant combination therapy is recommended by some guidelines, but only as a third-line treatment following stimulant monotherapy and stimulants combined with behavioral interventions to treat aggression in patients with ADHD. Some studies suggest efficacy/effectiveness for an antipsychotic and stimulant combination in the treatment of aggression and hyperactivity in children and adolescents. However, the data do not clearly demonstrate superiority compared to antipsychotic or psychostimulant monotherapy. Most studies were performed over short time periods, several lacked blinding, few studies used any placebo control, and no comparisons were made with behavioral interventions. There are concerns about the tolerability of combination therapy, but data do not suggest significantly worse adverse effects for combination compared to either antipsychotic or stimulant monotherapy. Conversely, and contrary to speculation, use of a stimulant does not significantly reduce metabolic effects of antipsychotics. Combination treatment with antipsychotics and psychostimulants is used frequently, and increasingly more often. Few studies have directly examined this combination for the treatment of ADHD and DBDs. Further studies are necessary to confirm the efficacy and tolerability of the concurrent use of antipsychotics and psychostimulants in children and adolescents.
authors.affiliation: British Columbia Mental Health and Addictions Research Institute, A3-938 W 28th Avenue, Vancouver, B.C. V5Z 4H4, Canada.
authors.forename: David
authors.initials: D
authors.lastname: Linton
authors.forename: Alasdair M
authors.initials: AM
authors.lastname: Barr
authors.forename: William G
authors.initials: WG
authors.lastname: Honer
authors.forename: Ric M
authors.initials: RM
authors.lastname: Procyshyn
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D019958:Attention Deficit and Disruptive Behavior Disorders / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D017410:Practice Guidelines as Topic
chemical_list: D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants
references.citation: Pediatrics. 2012 Jun;129(6):e1577-86
references.pmid: 22641763
references.citation: Neuropsychopharmacology. 2004 Jan;29(1):133-45
references.pmid: 14583740
references.citation: J Psychiatry Neurosci. 2007 Sep;32(5):331-8
references.pmid: 17823649
references.citation: Neuroscience. 1991;41(1):1-24
references.pmid: 1676137
references.citation: J Child Adolesc Psychopharmacol. 2009 Apr;19(2):101-9
references.pmid: 19364288
references.citation: Mol Psychiatry. 2005 Jan;10(1):79-104
references.pmid: 15289815
references.citation: J Child Adolesc Psychopharmacol. 2009 Oct;19(5):563-73
references.pmid: 19877981
references.citation: Am J Psychiatry. 2002 Aug;159(8):1337-46
references.pmid: 12153826
references.citation: J Child Adolesc Psychopharmacol. 2004 Summer;14(2):243-54
references.pmid: 15319021
references.citation: J Am Acad Child Psychiatry. 1984 May;23(3):295-8
references.pmid: 6145738
references.citation: Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008559
references.pmid: 22972123
references.citation: Health Serv Res. 2012 Oct;47(5):1836-60
references.pmid: 22946905
references.citation: J Child Adolesc Psychopharmacol. 2007 Feb;17(1):1-9
references.pmid: 17343549
references.citation: Psychiatr Serv. 2011 Jun;62(6):682-3
references.pmid: 21632741
references.citation: J Am Acad Child Adolesc Psychiatry. 2002 Sep;41(9):1026-36
references.pmid: 12218423
references.citation: Pediatrics. 2008 May;121(5):1002-9
references.pmid: 18450906
references.citation: Eur Child Adolesc Psychiatry. 2010 Apr;19(4):353-64
references.pmid: 19763664
references.citation: J Am Acad Child Adolesc Psychiatry. 2006 Jun;45(6):642-657
references.pmid: 16721314
references.citation: Arch Gen Psychiatry. 2006 Jun;63(6):679-85
references.pmid: 16754841
references.citation: J Am Acad Child Adolesc Psychiatry. 2002 Mar;41(3):253-61
references.pmid: 11886019
references.citation: J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):132-44
references.pmid: 12544173
references.citation: Health Aff (Millwood). 2009 Sep-Oct;28(5):w770-81
references.pmid: 19622537
references.citation: J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1001-10
references.pmid: 20855045
references.citation: Can J Psychiatry. 2012 Jan;57(1):52-8
references.pmid: 22296959
references.citation: J Clin Psychopharmacol. 2010 Dec;30(6):741-3
references.pmid: 21057241
references.citation: J Child Adolesc Psychopharmacol. 2009 Oct;19(5):553-61
references.pmid: 19877980
references.citation: Eur Neuropsychopharmacol. 2004 Jan;14(1):11-28
references.pmid: 14659983
references.citation: Arch Gen Psychiatry. 1976 Oct;33(10):1217-31
references.pmid: 971031
references.citation: Mol Psychiatry. 1998 Sep;3(5):386-96
references.pmid: 9774771
references.citation: J Am Acad Child Adolesc Psychiatry. 2007 May;46(5):558-565
references.pmid: 17450046
references.citation: J Am Acad Child Adolesc Psychiatry. 1999 Nov;38(11):1327-8
references.pmid: 10560215
references.citation: J Child Adolesc Psychopharmacol. 2007 Jun;17(3):334-47
references.pmid: 17630867
references.citation: Clin Pediatr (Phila). 1997 Jul;36(7):381-93
references.pmid: 9241475
references.citation: Eur Neuropsychopharmacol. 2011 Aug;21(8):600-20
references.pmid: 21550212
references.citation: Arch Pediatr Adolesc Med. 2004 Aug;158(8):753-9
references.pmid: 15289247
references.citation: J Child Adolesc Psychopharmacol. 2007 Jun;17(3):303-11
references.pmid: 17630864
references.citation: J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):145-61
references.pmid: 12544174
references.citation: J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):9-20
references.pmid: 18174821
references.citation: J Child Adolesc Psychopharmacol. 2011 Dec;21(6):537-43
references.pmid: 22136092
references.citation: J Child Adolesc Psychopharmacol. 2004 Fall;14(3):350-8
references.pmid: 15650492
references.citation: Trends Pharmacol Sci. 2010 Oct;31(10):484-97
references.pmid: 20674990
references.citation: J Clin Psychiatry. 2010 May;71(5):566-73
references.pmid: 20361903
references.citation: J Clin Psychiatry. 2011 May;72(5):655-70
references.pmid: 21658348
references.citation: J Child Adolesc Psychopharmacol. 2009 Dec;19(6):765-70
references.pmid: 20035595
references.citation: Psychiatry (Edgmont). 2010 Jun;7(6):18-23
references.pmid: 20622942
references.citation: Pharmacol Ther. 2012 Aug;135(2):113-22
references.pmid: 22565090